Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165,219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants.
Wu Z, Li Q, Liu Y, Lv H, Mo Z, Li F, Yu Q, Jin F, Chen W, Zhang Y, Huang T, Hu X, Xia W, Gao J, Zhou H, Bai X, Liu Y, Liang Z, Jiang Z, Chen Y, Zhang J, Du J, Yang B, Xing B, Xing Y, Dong B, Yang Q, Shi C, Yan T, Ruan B, Shi H, Fan X, Feng D, Lv W, Zhang D, Kong X, Zhou L, Que D, Chen H, Chen Z, Guo X, Zhou W, Wu C, Zhou Q, Liu Y, Qiao J, Wang Y, Li X, Duan K, Zhao Y, Xu G, Yang X. Wu Z, et al. Among authors: chen z, chen w, chen h, chen y. Virol Sin. 2022 Oct;37(5):724-730. doi: 10.1016/j.virs.2022.07.011. Epub 2022 Aug 1. Virol Sin. 2022. PMID: 35926726 Free PMC article. Clinical Trial.
Efficacy and safety of a live attenuated influenza vaccine in Chinese healthy children aged 3-17 years in one study center of a randomized, double-blind, placebo-controlled phase 3 clinical trial, 2016/17 season.
Wang S, Zheng Y, Jin X, Gan Z, Shao Y, Zhu C, Hu X, Liang Z, Chen Y, Xing B, Lv H, Xu N. Wang S, et al. Among authors: chen y. Vaccine. 2020 Aug 27;38(38):5979-5986. doi: 10.1016/j.vaccine.2020.07.019. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747213 Free article. Clinical Trial.
Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3-9-month intervals following two-dose inactivated vaccine (CoronaVac).
Liao Y, Chen Y, Chen B, Liang Z, Hu X, Xing B, Yang J, Zheng Q, Hua Q, Yan C, Lv H. Liao Y, et al. Among authors: chen b, chen y. Front Immunol. 2022 Nov 8;13:1017590. doi: 10.3389/fimmu.2022.1017590. eCollection 2022. Front Immunol. 2022. PMID: 36426361 Free PMC article. Clinical Trial.
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older.
Chen Y, Zhang X, Gong L, Liang Z, Hu X, Xing B, Liao Y, Yuan L, Chen G, Lv H. Chen Y, et al. Among authors: chen g. Expert Rev Vaccines. 2023 Jan-Dec;22(1):1079-1090. doi: 10.1080/14760584.2023.2274491. Epub 2023 Nov 8. Expert Rev Vaccines. 2023. PMID: 37877219 Free article. Clinical Trial.
165,219 results
You have reached the last available page of results. Please see the User Guide for more information.